New Amsterdam Pharma
NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib, a proprietary oral CETP inhibitor for lowering LDL-C in cardiovascular disease patients who remain uncontrolled on statin therapy, with EMA approval expected in H2 2026 and US commercialization planned directly while Menarini handles Europe under a €1B+ licensing deal.
- Company typePublic
- Founded2020
- HeadquartersNaarden, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What New Amsterdam Pharma does
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company developing oral, non-statin therapies for cardio-metabolic diseases, with primary focus on obicetrapib (TA-8995), a highly selective cholesteryl ester transfer protein (CETP) inhibitor. The compound reduces hepatic cholesterol, upregulates LDL receptor expression, and increases LDL clearance, with Phase 3 trials demonstrating 33–41% LDL-C reduction as monotherapy and 50% with a fixed-dose combination of obicetrapib and ezetimibe. NewAmsterdam is conducting six Phase 3 trials (PREVAIL, BROADWAY, BROOKLYN, TANDEM, REMBRANDT, RUBENS) plus a Phase 2 Alzheimer's program, targeting ASCVD patients, HeFH patients, statin-intolerant patients, and metabolic syndrome/T2D patients. The company is also exploring CETP inhibition in Alzheimer's disease following positive p-tau217 biomarker data showing 20.5% reduction in APOE4/4 carriers.
The company's revenue model relies entirely on future pharmaceutical product sales and licensing royalties, as it is pre-commercial with no material product revenue. In the US, NewAmsterdam is building a direct salesforce led by Chief Commercial Officer BJ Jones (former Biohaven Nurtec ODT launch lead) targeting the >€1B cardiovascular market with 51–100 employees and offices in Naarden (Netherlands HQ), Weston FL, Yardley PA, and Aventura FL. For Europe, NewAmsterdam signed an exclusive licensing deal with Menarini Group (potential deal value exceeding €1 billion in upfronts, milestones, and royalties) covering sales, marketing, and distribution. As of December 31, 2025, the company held approximately $729M in cash following $479M raised in a December 2024 public offering, supporting operations through anticipated EMA approval in H2 2026 and FDA approval post-PREVAIL CVOT readout.
New Amsterdam Pharma firmographics
Firmographics- Name
- New Amsterdam Pharma
- Legal name
- NewAmsterdam Pharma Corporation
- Website
- https://newamsterdampharma.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib, a proprietary oral CETP inhibitor for lowering LDL-C in cardiovascular disease patients who remain uncontrolled on statin therapy, with EMA approval expected in H2 2026 and US commercialization planned directly while Menarini handles Europe under a €1B+ licensing deal.
- Ownership category
- akta.pro rank
New Amsterdam Pharma industry classification
Industry- Product category
- Cardiovascular Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Specialty Care Pharmaceuticals (HLAIAAAB), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where New Amsterdam Pharma is headquartered
LocationHeadquarters
- HQ city
- Naarden
- HQ country
- Netherlands
- HQ region
- Europe
Offices4 records
Markets served
New Amsterdam Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical stage company planning to commercialize obicetrapib for cardiovascular disease patients with elevated LDL-C. Revenue will come from direct pharmaceutical product sales in markets where approved.
- European Licensing (Menarini): Licensing deal with Menarini Group for exclusive commercialization rights in Europe, with total potential deal value exceeding €1 billion. This represents a combination of upfront payments, development milestones, and royalty payments on net sales.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
New Amsterdam Pharma product offering
Product offeringCore offering
NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib (TA-8995), an oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). The lead candidate is being developed as both a monotherapy and a fixed-dose combination with ezetimibe, supported by Phase 3 clinical trials demonstrating 33-50% LDL-C reductions, with an FDA NDA submission and EMA marketing authorization application under review.
Product overview
New Amsterdam Pharma is a late-stage clinical biopharmaceutical company developing a pipeline of oral, non-statin medicines for cardiovascular disease and other lipid-related conditions. The core product is obicetrapib (TA-8995), a highly selective CETP inhibitor, which is being developed both as a monotherapy and as a fixed-dose combination with ezetimibe. The company has multiple Phase 3 registrational trials underway including PREVAIL (cardiovascular outcomes), BROADWAY, BROOKLYN, TANDEM, REMBRANDT, and RUBENS, as well as Phase 2 programs for Alzheimer's disease and additional indications. The company is also exploring applications of CETP inhibition beyond cardiovascular disease, including potential treatment for Alzheimer's disease and type 2 diabetes.
Differentiator
Problem solved
Functional benefit
Products and services
- Obicetrapib (TA-8995) Investigational, oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor being studied as an adjunct to maximally tolerated lipid-lowering therapies for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH).
- Obicetrapib + Ezetimibe Fixed-Dose Combination Fixed-dose combination of obicetrapib (CETP inhibitor) with ezetimibe (NPC1L1 inhibitor) for patients with ASCVD, HeFH, or CV risk equivalent, designed to provide synergistic LDL-C reduction alongside maximally tolerated lipid-lowering therapies; demonstrated 50% LDL-C reduction in TANDEM Phase 3 trial.
Quantifiable outcome
- 33% LDL-C reduction (BROADWAY trial, p < 0.0001)
- +6 more outcomes
Companies that use New Amsterdam Pharma
Customer profileSegments5 records
Ideal customer profiles2 records
New Amsterdam Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
New Amsterdam Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Menarini GroupflagshipExclusive licensing agreement for commercialization of obicetrapib in Europe. Total potential deal value exceeds €1 billion. Menarini will handle all commercial activities including sales, marketing, and distribution in European territories. EMA decision expected in H2 2026.
- Menarini GroupflagshipEuropean commercialization rights exclusively licensed to Menarini Group following regulatory approval.
- Victorian Heart InstitutecorePhase 3 clinical partnership for cardiovascular outcomes trial PREVAIL. This partnership was recognized at the Citeline Awards in 2025.
Scale indicators9 records
Recent moves13 records
Expansion highlights6 records
New Amsterdam Pharma competitors and assessment
Company assessmentDirect peers
- Esperion Therapeutics: Commercial-stage company marketing bempedoic acid (Nexletol/Nexlizet), an oral non-statin LDL-C lowering therapy targeting the same statin-intolerant and ASCVD patient population as obicetrapib. Most directly comparable peer given oral mechanism, CV risk-reduction positioning, and overlapping prescriber base.
- Amarin Corporation: Markets Vascepa/icosapent ethyl for cardiovascular risk reduction in statin-treated high-triglyceride patients. Directly comparable as a focused cardiovascular outcomes-driven lipid franchise targeting residual CV risk in ASCVD patients on maximally tolerated statins.
- Madrigal Pharmaceuticals: Late-stage cardiometabolic company that achieved FDA approval of resmetirom (Rezdiffra) for MASH. Closely comparable as a focused, late-stage biopharma commercializing a first-in-class cardiometabolic therapy with strong KOL backing and a similar go-to-market profile in specialty prescribing channels.
- Lexicon Pharmaceuticals: Commercial-stage cardiometabolic company marketing Zynquista (sotagliflozin, an SGLT1/2 inhibitor) for heart failure and diabetes. Comparable as a small-cap oral cardiometabolic franchise commercializing through a targeted US specialty sales channel.
Broad incumbents
- Novartis: Markets Leqvio (inclisiran), a twice-yearly subcutaneous siRNA for LDL-C lowering, providing a major competitive alternative to obicetrapib's oral, once-daily profile. Comparable as a broad incumbent in cardiovascular risk management with deep commercial reach globally.
- Amgen: Markets Repatha (evolocumab), the leading PCSK9 inhibitor for LDL-C reduction, and was the original developer of obicetrapib before divesting it to NewAmsterdam in 2020. Directly relevant incumbent competitor and historical licensor of the anchor asset.
- Regeneron: Co-markets Praluent (alirocumab) PCSK9 inhibitor with Sanofi for LDL-C lowering in ASCVD and HeFH. Comparable as an established incumbent in the same physician call point and same non-statin LDL-C lowering category.
Emerging players
- Verve Therapeutics: Clinical-stage genetic medicines company developing in vivo base-editing therapies for cardiovascular disease, including LDL-C lowering. Comparable as a next-generation lipid-lowering platform targeting the same ASCVD patient population with a differentiated (one-time treatment) modality.
- Ionis Pharmaceuticals: Develops antisense oligonucleotide therapies including olezarsen for dyslipidemia and cardiometabolic disease. Comparable as an emerging RNA-targeted lipid franchise competing in the residual CV risk space alongside oral and biologic alternatives to obicetrapib.
- BridgeBio Pharma: Cardiometabolic-focused biopharma with acoramidis (Attruby) approved for ATTR cardiomyopathy and a pipeline spanning cardiovascular and metabolic disease. Comparable as a focused late-stage cardiometabolic specialist with KOL credibility and recent cardiovascular launch experience.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
New Amsterdam Pharma social profiles
Digital presenceNew Amsterdam Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
New Amsterdam Pharma leadership team
Management profileNumber of profiles
Profiles17 records
New Amsterdam Pharma funding detail
Funding detailFunding overview
Funding rounds6 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
New Amsterdam Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about New Amsterdam Pharma
What does New Amsterdam Pharma do?
NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib (TA-8995), an oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). The lead candidate is being developed as both a monotherapy and a fixed-dose combination with ezetimibe, supported by Phase 3 clinical trials demonstrating 33-50% LDL-C reductions, with an FDA NDA submission and EMA marketing authorization application under review.
Is New Amsterdam Pharma a public or private company?
New Amsterdam Pharma is a public company. It is classified as public and is currently operating.
When was New Amsterdam Pharma founded?
New Amsterdam Pharma was founded in 2020. It employs 101 to 250 people.
Where is New Amsterdam Pharma based?
New Amsterdam Pharma is headquartered in Naarden, Netherlands, in the Europe region.
How does New Amsterdam Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are european Licensing (Menarini).
Who are New Amsterdam Pharma's main competitors?
Direct peers on record are Esperion Therapeutics, Amarin Corporation, Madrigal Pharmaceuticals and Lexicon Pharmaceuticals. Broad incumbents are Novartis, Amgen and Regeneron. Emerging players are Verve Therapeutics, Ionis Pharmaceuticals and BridgeBio Pharma.
Does New Amsterdam Pharma have an API?
No public API is recorded for New Amsterdam Pharma.
What industry is New Amsterdam Pharma in?
New Amsterdam Pharma's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.